

SUPPLEMENTAL TABLE 1
Respondents' Top 3 Concerns/Issues, by Radiopharmaceutical Therapy

Radiopharmaceutical Therapy	Percentage (n)
Oral ¹³¹ I (≤33 mCi)	
Referring physicians prefer to manage patients.	35% (33)
I have concerns about the radiation safety.	30% (28)
Provides poor payment for the time and effort in the administration process.	26% (24)
Oral ¹³¹ I (>33 mCi)	
I have concerns about the radiation safety.	40% (38)
I have concerns about the dosimetry procedures.	39% (37)
There might be unexpected late side effects.	33% (31)
²²³ Ra (Xofigo)	
Treatment is too expensive.	44% (43)
Referring physicians prefer to manage treatment.	21% (21)
Provides poor payment for the time and effort in the administration process.	20% (20)
⁹⁰ Y-microspheres (SIRSpheeres and TheraSpheres)	
Treatment is too expensive.	41% (39)
I have concerns about the dosimetry procedure.	30% (28)
I am not adequately trained to be comfortable administering this treatment.	30% (28)
¹⁷⁷ Lu-DOTATATE (Lutathera)	
Treatment is too expensive.	55% (52)
I have concerns about the dosimetry procedure.	24% (23)
There might be unexpected late side effects.	21% (20)
¹³¹ I-MIBG (Azedra or generic)	
Treatment is too expensive.	33% (30)
I have concerns about the radiation safety.	32% (29)
I have concerns about the dosimetry procedure.	28% (25)
⁹⁰ Y anti-CD 20 (Zevalin)	
Treatment is too expensive.	42% (36)
Referring physicians prefer to manage treatment.	35% (30)
Provides poor payment for the time and effort in the administration process.	20% (17)
¹⁵³ Sm-EDTMP (Quadramet) or ⁸⁹ Sr (Metastron)	
Referring physicians prefer to manage treatment.	37% (31)
There might be unexpected late side effects.	27% (23)
Treatment does not have enough reported randomized studies.	19% (16)
Prostate radionuclide therapy	
I don't have sufficient information about this procedure.	34% (30)
Treatment does not have enough reported randomized studies.	30% (27)
I have concerns about the radiation safety.	19% (17)
Radionuclide therapy for joints	
I don't have sufficient information about this procedure.	43% (38)
I am not adequately trained to be comfortable administering this treatment.	35% (31)
Referring physicians prefer to manage treatment.	22% (19)